Several drugs, which interfere with vascular endothelial growth factor (VEGF) signaling, have been approved for the treatment of advanced carcinomas and the wet form of macular degeneration (Barakat & Kaiser, 2009; Welti et al, 2013). This evidence concerns the gene VEGFA and carcinoma.